OS Therapies (NYSEAMERICAN:OSTX) Stock Price Down 2.5% - Time to Sell?

Key Points

• OS Therapies shares fell 2.5% to $1.55 in Monday trading, with volume 34% above average. The company has a market capitalization of approximately $71.5 million and remains unprofitable.
• Analyst sentiment is generally positive, with three Buy ratings and one Hold rating producing a consensus “Moderate Buy” rating and an average price target of $13.33—well above the current share price.
• The clinical-stage biopharmaceutical company reported a quarterly loss of $0.20 per share, while analysts expect a full-year loss of $0.77 per share. Its pipeline focuses on treatments for osteosarcoma and other solid tumors, including OST-HER2 and an antibody-drug conjugate platform.

OS Therapies Incorporated (NYSEAMERICAN:OSTX - Get Free Report)'s share price dropped 2.5% during trading on Monday . The company traded as low as $1.4602 and last traded at $1.55. 438,582 shares traded hands during trading, an increase of 34% from the average session volume of 328,382 shares. The stock had previously closed at $1.59.

Analyst Upgrades and Downgrades

OSTX has been the subject of a number of recent analyst reports. Roth Capital began coverage on OS Therapies in a research report on Thursday, July 9th. They set a "buy" rating and a $7.00 target price for the company. Lake Street Capital decreased their price target on OS Therapies from $14.00 to $13.00 and set a "buy" rating on the stock in a research report on Tuesday, May 19th. D. Boral Capital reaffirmed a "buy" rating and issued a $20.00 price target on shares of OS Therapies in a research note on Thursday, April 30th. Finally, Zacks Research raised shares of OS Therapies from a "strong sell" rating to a "hold" rating in a research report on Thursday, June 4th. Three research analysts have rated the stock with a Buy rating and one has issued a Hold rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and a consensus target price of $13.33.

OS Therapies Stock Down 2.5%

The firm has a 50 day simple moving average of $1.65 and a two-hundred day simple moving average of $1.57. The stock has a market capitalization of $71.50 million, a P/E ratio of -1.42 and a beta of -0.72.

OS Therapies (NYSEAMERICAN:OSTX - Get Free Report) last issued its quarterly earnings results on Friday, August 14th. The company reported ($0.20) earnings per share (EPS) for the quarter. On average, research analysts predict that OS Therapies Incorporated will post -0.77 earnings per share for the current year.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently bought and sold shares of the business. AXQ Capital LP bought a new position in shares of OS Therapies in the second quarter worth about $47,000. State Street Corp grew its holdings in shares of OS Therapies by 16.3% during the 4th quarter. State Street Corp now owns 58,500 shares of the company's stock valued at $82,000 after purchasing an additional 8,200 shares during the last quarter. Jane Street Group LLC acquired a new position in OS Therapies during the 4th quarter worth approximately $39,000. Geode Capital Management LLC increased its position in OS Therapies by 31.1% during the 4th quarter. Geode Capital Management LLC now owns 246,038 shares of the company's stock worth $344,000 after purchasing an additional 58,350 shares in the last quarter. Finally, Susquehanna International Group LLP bought a new position in OS Therapies in the 3rd quarter valued at approximately $29,000.

OS Therapies Company Profile

OS Therapies Incorporated, a clinical stage biopharmaceutical company, focuses on the identification, development, and commercialization of treatments for osteosarcoma and other solid tumors in the United States. Its pipeline includes OST-HER2, an off-the-shelf immunotherapy for osteosarcoma patients; and OST-tunable drug conjugate (OST-tADC), an antibody-drug conjugate technology, with a plug-and-play platform that features tunable pH sensitive silicone linkers. OS Therapies Incorporated was incorporated in 2018 and is based in Rockville, Maryland.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source